1 |
Rôle de l'interaction entre la protéine virale EBNA1 et le facteur cellulaire RCC1 dans la persistance du génome du virus d'Epstein-Barr / Role of the interaction between the viral protein EBNA1 and the cellular factor RCC1 for the persistance of the Epstein-Barr Virus genomeDeschamps, Thibaut 18 September 2015 (has links)
Le virus d’Epstein-Barr (EBV) est un herpesvirus dont la séroprévalence est d’environ 90 % de la population adulte mondiale. EBV est associé à de nombreuses pathologies tumorales. La primo infection conduit à l’établissement du virus sous forme latente dans les lymphocytes B mémoires. Au sein de ces cellules B, le génome viral est sous la forme d’un épisome, un ADN circulaire double brin, et une fraction restreinte de gènes viraux est exprimée. Afin de se maintenir aux cours des divisions cellulaires, le génome viral est répliqué en phase S par la machinerie cellulaire et ségrégé lors de la mitose dans chaque cellules filles. La réplication et la ségrégation du génome viral nécessitent 2 facteurs viraux que sont la protéine virale EBNA1 (Epstein-Barr Nuclear Antigen 1) et la région oriP sur le génome viral. En phase S, EBNA1 interagit directement avec l’oriP et y recrute le complexe de pré-réplication de l’ADN. En mitose, EBNA1 ancre l’épisome à la chromatine ce qui permet une ségrégation efficace. Les mécanismes d’interaction entre EBNA1 et la chromatine reste encore flou. Au cours de notre travail, nous avons identifié la protéine RCC1 comme un partenaire potentiel pour la protéine EBNA1 pouvant être impliqué dans l’ancrage d’EBNA1 à la chromatine. Nous avons validé cette interaction et caractérisé les régions d’interactions pour ces deux protéines. Par ailleurs nous avons démontré que RCC1 est recrutée sur l’oriP en présence d’EBNA1 et que ces deux protéines interagissent en mitose. À la lumière de nos résultats et des données de la littérature, nous proposons que l’interaction d’EBNA1 avec la chromatine est dynamique et implique à la fois des interactions directes (AT-Hook, interaction avec les nucléosomes) mais aussi des facteurs cellulaires (RCC1, EBP2 et HMGB2). / Epstein-Barr virus (EBV) is a ubiquitous herpesvirus associated with several human cancers. In proliferating latently-infected cells, the EBV genome persists as a circular plasmid that is replicated once per cell cycle and partitioned at mitosis. Both of these processes require a single viral protein, Epstein Barr nuclear antigen 1 (EBNA1), which binds to two clusters of cognate binding sites within the origin of plasmid replication (oriP). EBNA1 plays an essential role both in viral episome replication, by recruiting the cellular complex of DNA replication onto the oriP, and in the efficient segregation of the viral episomes, by tethering the viral DNA onto the mitotic chromosomes. Whereas the mechanisms of viral DNA replication have been well documented, the mechanisms involved in tethering EBNA1 to the cellular chromatin are far from being understood. Here we have identified Regulator of Chromosome Condensation 1 (RCC1) as a novel EBNA1 cellular partner. RCC1 is the only known nuclear guanine nucleotide exchange factor (RanGEF) for the small GTPase Ran enzyme. RCC1, associated with chromatin, is involved in the formation of RanGTP gradients critical for nucleo-cytoplasmic transport, mitotic spindle formation, and nuclear envelope reassembly after mitosis. We have used several approaches to demonstrate a direct interaction between these two proteins and to identify the regions. involved Moreover, by using Chromatin ImmunoPrecipitation assay (ChIP) we have shown that RCC1 is enriched in the oriP region of mini viral replicons in a manner dependent on EBNA1. Finally, by using a combination of confocal microscopy and FRET analysis to follow the dynamics of interaction between the two proteins throughout the cell cycle, we have demonstrated that EBNA1 and RCC1 closely associate on the chromosomes during metaphase. Taken together, our data strongly suggest an essential role for RCC1 in tethering EBNA1 - linked to the viral episome - to the metaphasic chromosomes. Our results and those of others lead us to the idea that the interaction between EBNA1 with the cellular chromosomes requires several factors such as direct interactions or cellular proteins and these interactions are complementary and / or redundant.
|
2 |
Novel Ran-RCC1 inhibitory peptide-loaded nanoparticles have anti-cancer efficacy in vitro and in vivoHaggag, Y.A., Matchett, K.B., Falconer, Robert A., Isreb, Mohammad, Jones, Jason, Faheem, A., McCarron, P., El-Tanani, Mohamed 30 October 2019 (has links)
Yes / The delivery of anticancer agents to their subcellular sites of action is a significant challenge
for effective cancer therapy. Peptides, which are integral to several oncogenic pathways, have
significant potential to be utilised as cancer therapeutics due to their selectivity, high potency
and lack of normal cell toxicity. Novel Ras protein-Regulator of chromosome condensation 1
(Ran-RCC1) inhibitory peptides designed to interact with Ran, a novel therapeutic target in
breast cancer, were delivered by entrapment into polyethylene glycol-poly (lactic-co-glycolic acid)
PEG-PLGA polymeric nanoparticles (NPs). A modified double emulsion solvent evaporation
technique was used to optimise the physicochemical properties of these peptide-loaded biodegradable
NPs. The anti-cancer activity of peptide-loaded NPs was studied in vitro using Ran-expressing
metastatic breast (MDA-MB-231) and lung cancer (A549) cell lines, and in vivo using Solid Ehrlich
Carcinoma-bearing mice. The anti-metastatic activity of peptide-loaded NPs was investigated using
migration, invasion and colony formation assays in vitro. A PEG-PLGA-nanoparticle encapsulating
N-terminal peptide showed a pronounced antitumor and anti-metastatic action in lung and breast
cancer cells in vitro and caused a significant reduction of tumor volume and associated tumor growth
inhibition of breast cancer model in vivo. These findings suggest that the novel inhibitory peptides
encapsulated into PEGylated PLGA NPs are delivered effectively to interact and deactivate Ran.
This novel Ran-targeting peptide construct shows significant potential for therapy of breast cancer
and other cancers mediated by Ran overexpression.
|
3 |
Integrative and Comprehensive Pancancer Analysis of Regulator of Chromatin Condensation 1 (RCC1)Wu, Changwu, Duan, Yingjuan, Gong, Siming, Kallendrusch, Sonja, Schopow, Nikolas, Osterhoff, Georg 11 December 2023 (has links)
Regulator of Chromatin Condensation 1 (RCC1) is the only known guanine nucleotide
exchange factor that acts on the Ras-like G protein Ran and plays a key role in cell cycle regulation.
Although there is growing evidence to support the relationship between RCC1 and cancer, detailed
pancancer analyses have not yet been performed. In this genome database study, based on The
Cancer Genome Atlas, Genotype-Tissue Expression and Gene Expression Omnibus databases, the
potential role of RCC1 in 33 tumors’ entities was explored. The results show that RCC1 is highly
expressed in most human malignant neoplasms in contrast to healthy tissues. RCC1 expression is
closely related to the prognosis of a broad variety of tumor patients. Enrichment analysis showed
that some tumor-related pathways such as “cell cycle” and “RNA transport” were involved in the
functional mechanism of RCC1. In particular, the conducted analysis reveals the relation of RCC1
to multiple immune checkpoint genes and suggests that the regulation of RCC1 is closely related
to tumor infiltration of cancer-associated fibroblasts and CD8+ T cells. Coherent data demonstrate
the association of RCC1 with the tumor mutation burden and microsatellite instability in various
tumors. These findings provide new insights into the role of RCC1 in oncogenesis and tumor
immunology in various tumors and indicate its potential as marker for therapy prognosis and
targeted treatment strategies.
|
4 |
Ran GTPase in Nuclear Envelope Formation and Cancer MetastasisMatchett, K.B., McFarlane, S., Hamilton, S.E., Eltuhamy, Y.S.A., Davidson, M.A., Murray, J.T., Faheem, A.M., El-Tanani, Mohamed 2014 January 1924 (has links)
No / Ran is a small ras-related GTPase that controls the nucleocytoplasmic exchange of macromolecules across the nuclear envelope. It binds to chromatin early during nuclear formation and has important roles during the eukaryotic cell cycle, where it regulates mitotic spindle assembly, nuclear envelope formation and cell cycle checkpoint control. Like other GTPases, Ran relies on the cycling between GTP-bound and GDP-bound conformations to interact with effector proteins and regulate these processes. In nucleocytoplasmic transport, Ran shuttles across the nuclear envelope through nuclear pores. It is concentrated in the nucleus by an active import mechanism where it generates a high concentration of RanGTP by nucleotide exchange. It controls the assembly and disassembly of a range of complexes that are formed between Ran-binding proteins and cellular cargo to maintain rapid nuclear transport. Ran also has been identified as an essential protein in nuclear envelope formation in eukaryotes. This mechanism is dependent on importin-β, which regulates the assembly of further complexes important in this process, such as Nup107–Nup160. A strong body of evidence is emerging implicating Ran as a key protein in the metastatic progression of cancer. Ran is overexpressed in a range of tumors, such as breast and renal, and these perturbed levels are associated with local invasion, metastasis and reduced patient survival. Furthermore, tumors with oncogenic KRAS or PIK3CA mutations are addicted to Ran expression, which yields exciting future therapeutic opportunities.
|
Page generated in 0.2035 seconds